NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR), whose physics-based software platform is transforming the way therapeutics and materials are discovered, today announced financial results for the third quarter ended September 30, 2021, and provided an update on the company.
“We are very pleased with the progress we have made across the business so far this year. The level of engagement with senior R&D leaders across pharma and the growth we are seeing in new software customers suggests a shift in the drug discovery paradigm and a push to incorporate advanced computational approaches into projects at all stages,” stated Ramy Farid, Ph.D., chief executive officer at Schrödinger. “As we approach year-end, we are continuing to focus on key strategic priorities, including advancing our internal pipeline. We are on track to submit an IND to the FDA for our MALT1 inhibitor program in the first half of next year, and we look forward to presenting additional preclinical data for this program at the American Society of Hematology Annual Meeting next month. We also recently selected a development candidate and initiated IND-enabling studies for our CDC7 inhibitor program, and we added a new oncology target, our fifth internal program, to our pipeline.”
Recent Business Highlights
Collaborations Highlight Opportunities and Progress Across the Business
-
Entered collaboration with Centessa Pharmaceuticals Subsidiary, Orexia Therapeutics, focused on novel orexin receptor agonists: In October, Schrödinger and Centesa Pharmaceuticals Subsidiary, Orexia Therapeutics, announced a collaboration focused on the discovery of novel therapeutics targeting the orexin-2 receptor, which is known to play a role in a broad spectrum of sleep disorders, including narcolepsy. The collaboration provides Orexia with substantial access to Schrödinger’s entire computational platform as well as Schrödinger’s extensive expertise in ultra-large-scale deployment of its technology.
Under the terms of the agreement, Orexia is responsible for preclinical research activities, clinical development and commercialization of future product candidates discovered under the collaboration. Schrödinger received an upfront software access payment and may become eligible to receive certain preclinical, development, regulatory and commercial milestone payments, as well as low single digit royalties on global net sales.
- Formed strategic collaboration with MD Anderson to accelerate development of WEE1 program: In October, Schrödinger and The University of Texas MD Anderson Cancer Center announced a two-year strategic research collaboration focused on accelerating and optimizing the development of Schrödinger’s WEE1 inhibitor program. The goal of the collaboration is to accelerate and optimize the clinical development path for Schrödinger’s WEE1 program through molecular biomarker-driven tumor type prioritization and patient stratification and to validate biomarkers to predict response or resistance to a WEE1 inhibitor. The joint team will seek to prioritize clinical studies of a WEE1 inhibitor as a single agent in selected cancer indications and in combinations for defined clinical subpopulations.
- Completion of $100 million financing by strategic partner ShouTi: In October, Schrödinger’s partner, ShoutTi Inc., announced a $100 million series B financing to advance the company’s discovery platform, leveraging Schrödinger’s computational platform and expertise, and ShouTi’s structural biology and drug discovery expertise to design orally available medicines with properties that aim to overcome current limitations of biologic and peptide drugs. Schrödinger is a co-founder of ShouTi, which is advancing a pipeline focused on chronic diseases with high medical need, including cardiovascular, metabolic and pulmonary conditions.
- Provided update on collaboration with Bristol Myers Squibb: Schrödinger today announced that the companies have prioritized an undisclosed precision oncology target that will replace HIF-2 alpha. Additionally, Schrödinger and Bristol Myers Squibb recently expanded their collaboration with a new agreement to discover, develop and commercialize bifunctional degraders.
Internal Programs Expanding and Advancing
-
New preclinical data from multiple MALT1 inhibitors to be presented at ASH: Last week, Schrödinger announced that new preclinical data from its MALT1 program will be presented at the ASH 2021 Annual Meeting, which is being held December 11 - 14 virtually and in person in Atlanta, GA. The poster presentation, “Characterization of Potent Paracaspase MALT1 Inhibitors for Hematological Malignancies” (Abstract #1187), is scheduled to take place on Saturday, December 11, from 5:30 p.m. - 7:30 p.m. ET. MALT1 is considered a potential therapeutic target for several non-Hodgkin’s B-cell lymphomas as well as chronic lymphocytic leukemia.
Schrödinger expects to submit an investigational new drug (IND) application to the U.S. Food and Drug Administration for its MALT1 program in the first half of 2022.
- Development candidate selected for CDC7 program: Schrödinger today announced that it selected a development candidate and has initiated IND-enabling studies for its CDC7 inhibitor program. CDC7 is thought to be linked to cancer cells’ proliferative capacity and ability to bypass normal DNA damage responses. Targeting proteins that play important roles in DNA replication and replication stress, such as CDC7, is gaining momentum as a therapeutic approach for cancer.
- Internal pipeline expanded to five programs: Schrödinger continued to advance its discovery efforts and today announced that the company further expanded its internal pipeline with the addition of a fifth program, which is an undisclosed oncology target.
Third Quarter 2021 Financial Results
- Total revenue was $29.9 million for the third quarter of 2021, a 16 percent increase compared to the third quarter of 2020.
- Software revenue was $24.3 million for the third quarter of 2021, compared to $22.9 million for the third quarter of 2020. The six percent growth observed year-over-year was primarily due to increased sales from existing customers and the addition of new customers, partially offset by multi-year contracts that were executed in the third quarter of 2020, as well as the completion of a research project that was active in the third quarter of 2020.
- Drug discovery revenue was $5.6 million for the third quarter of 2021, compared to $2.9 million in the third quarter of 2020. Third quarter 2021 drug discovery revenue included the recognition of $4.4 million of revenue from the company’s collaboration with Bristol Myers Squibb.
- Gross profit was $11.1 million in the third quarter of 2021, compared to $15.3 million in the third quarter in 2020. Software gross margin was 73 percent in the third quarter of 2021, compared to 81 percent for the same period in the prior year, reflecting planned investments to drive and support large-scale adoption of Schrödinger’s platform as well as increased royalty expenses in the quarter.
- Operating expenses for the third quarter of 2021 were $45.8 million, compared to $30.7 million in the third quarter of 2020, driven by expenses required to scale the company’s business, advance its internal drug discovery programs and continue to build a public company infrastructure.
- Other expense, which included changes in fair value of equity investments and interest income, was $0.3 million in the third quarter of 2021 compared to income of $18.7 million for the third quarter of 2020 due to adjustments to the fair value of the company’s equity investments.
- Net loss, after adjusting for non-controlling interest, was $35.0 million for the third quarter of 2021, compared to net income of $3.9 million for the third quarter of 2020, driven by adjustments to the fair value of the company’s equity investments as well as planned investments to advance the company’s growth strategy.
- Cash, cash equivalents, restricted cash and marketable securities as of September 30, 2021, were $600.2 million, compared to $616.6 million as of June 30, 2021.
Full-Year 2021 Financial Outlook
As of November 10, 2021, Schrödinger expects total revenue to range from $124 million to $134 million for the fiscal year ending December 31, 2021. The company is maintaining its full-year software revenue expectation of $102 million to $110 million. The company is adjusting its full-year drug discovery revenue expectation to a range of $22 million to $24 million, updated from a previous expectation of $22 million to $32 million, primarily due to the timing of anticipated milestones from collaborators.
Schrödinger continues to aggressively fund R&D to advance its technology and drug discovery pipeline. The company continues to expect operating expense growth to be higher than the 42 percent annual growth rate reported in 2020 and expects software gross margin to be lower than the 81 percent reported in 2020.
Webcast and Conference Call Information
Schrödinger will host a conference call to discuss its third quarter financial results on Wednesday, November 10, 2021, at 4:30 p.m. ET. The conference call can be accessed live by dialing (833) 727-9520 (domestic) or +1 (830) 213-7697 (international) and referring to conference ID 2484045. The webcast can also be accessed under “News & Events” in the investors section of Schrödinger’s website, https://ir.schrodinger.com/news-and-events/event-calendar. The archived webcast will be available on Schrödinger’s website for approximately 90 days following the event.
About Schrödinger
Schrödinger is transforming the way therapeutics and materials are discovered. Schrödinger has pioneered a physics-based software platform that enables discovery of high-quality, novel molecules for drug development and materials applications more rapidly and at lower cost compared to traditional methods. The software platform is used by biopharmaceutical and industrial companies, academic institutions, and government laboratories around the world. Schrödinger’s multidisciplinary drug discovery team also leverages the software platform to advance collaborative programs and its own pipeline of novel therapeutics to address unmet medical needs.
Founded in 1990, Schrödinger has over 500 employees and is engaged with customers and collaborators in more than 70 countries. To learn more visit www.schrodinger.com and follow us on LinkedIn and Twitter.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995 including, but not limited to those regarding Schrödinger’s expectations about the speed and capacity of its computational platform, the company’s financial outlook for the fiscal year ending December 31, 2021, the company’s plans to continue to invest in research and its strategic plans to accelerate the growth of its software business and advance its collaborative and internal drug discovery programs, the potential to accelerate and optimize the company’s WEE1 program through its research collaboration with MD Anderson, the clinical potential and favorable properties of the company’s CDC7, MALT1 and WEE1 inhibitors, the timing of potential IND submissions for its internal drug discovery programs, the ability to realize potential milestones, royalties or other payments under its collaborations, including with BMS and Orexia Therapeutics, as well as the company’s expectations related to the use of its cash, cash equivalents and marketable securities. Statements including words such as “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would” and statements in the future tense are forward-looking statements. These forward-looking statements reflect Schrödinger’s current views about its plans, intentions, expectations, strategies and prospects, which are based on the information currently available to the company and on assumptions the company has made. Actual results may differ materially from those described in these forward-looking statements and are subject to a variety of assumptions, uncertainties, risks and important factors that are beyond Schrödinger’s control, including the demand for its software solutions, the ability to further develop its computational platform, the reliance upon third-party providers of cloud-based infrastructure to host its software solutions, the reliance upon its third-party drug discovery and research collaborators, the uncertainties inherent in drug development and commercialization, such as the conduct of research activities and the timing of and its ability to initiate and complete preclinical studies and clinical trials, whether results from preclinical studies will be predictive of the results of later preclinical studies and clinical trials, uncertainties associated with the regulatory review of IND submissions, clinical trials and applications for marketing approvals, the ability to retain and hire key personnel and the direct and indirect impacts of the ongoing COVID-19 pandemic on its business and other risks detailed under the caption “Risk Factors” and elsewhere in the company’s Securities and Exchange Commission filings and reports, including its Quarterly Report on Form 10-Q for the quarter ended September 30, 2021, filed with the Securities and Exchange Commission on November 10, 2021, as well as future filings and reports by Schrödinger. Any forward-looking statements contained in this press release speak only as of the date hereof. Except as required by law, the company undertakes no duty or obligation to update any forward-looking statements contained in this press release as a result of new information, future events, changes in expectations or otherwise.
Condensed Consolidated Statements of Operations (Unaudited) |
|
|||||||||||||||
(in thousands, except for share and per share amounts) |
|
|||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended
|
|
|
Nine Months Ended
|
|
||||||||||
|
|
2021 |
|
|
2020 |
|
|
2021 |
|
|
2020 |
|
||||
Revenues: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Software products and services |
|
$ |
24,280 |
|
|
$ |
22,861 |
|
|
$ |
74,672 |
|
|
$ |
67,573 |
|
Drug discovery |
|
|
5,570 |
|
|
|
2,936 |
|
|
|
17,089 |
|
|
|
7,490 |
|
Total revenues |
|
|
29,850 |
|
|
|
25,797 |
|
|
|
91,761 |
|
|
|
75,063 |
|
Cost of revenues: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Software products and services |
|
|
6,611 |
|
|
|
4,334 |
|
|
|
18,158 |
|
|
|
12,197 |
|
Drug discovery |
|
|
12,124 |
|
|
|
6,191 |
|
|
|
34,344 |
|
|
|
18,386 |
|
Total cost of revenues |
|
|
18,735 |
|
|
|
10,525 |
|
|
|
52,502 |
|
|
|
30,583 |
|
Gross profit |
|
|
11,115 |
|
|
|
15,272 |
|
|
|
39,259 |
|
|
|
44,480 |
|
Operating expenses: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Research and development |
|
|
23,219 |
|
|
|
17,019 |
|
|
|
65,759 |
|
|
|
47,376 |
|
Sales and marketing |
|
|
5,556 |
|
|
|
3,969 |
|
|
|
16,175 |
|
|
|
13,120 |
|
General and administrative |
|
|
17,014 |
|
|
|
9,729 |
|
|
|
46,253 |
|
|
|
28,316 |
|
Total operating expenses |
|
|
45,789 |
|
|
|
30,717 |
|
|
|
128,187 |
|
|
|
88,812 |
|
Loss from operations |
|
|
(34,674 |
) |
|
|
(15,445 |
) |
|
|
(88,928 |
) |
|
|
(44,332 |
) |
Other (expense) income: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(Loss) gain on equity investments |
|
|
— |
|
|
|
— |
|
|
|
(1,781 |
) |
|
|
4,156 |
|
Change in fair value |
|
|
(627 |
) |
|
|
18,233 |
|
|
|
19,279 |
|
|
|
23,513 |
|
Interest income |
|
|
286 |
|
|
|
463 |
|
|
|
1,063 |
|
|
|
1,732 |
|
Total other (expense) income |
|
|
(341 |
) |
|
|
18,696 |
|
|
|
18,561 |
|
|
|
29,401 |
|
(Loss) income before income taxes |
|
|
(35,015 |
) |
|
|
3,251 |
|
|
|
(70,367 |
) |
|
|
(14,931 |
) |
Income tax (benefit) expense |
|
|
(4 |
) |
|
|
(35 |
) |
|
|
137 |
|
|
|
120 |
|
Net (loss) income |
|
|
(35,011 |
) |
|
|
3,286 |
|
|
|
(70,504 |
) |
|
|
(15,051 |
) |
Net loss attributable to noncontrolling interest |
|
|
(4 |
) |
|
|
(566 |
) |
|
|
(824 |
) |
|
|
(1,727 |
) |
Net (loss) income attributable to Schrödinger common and limited common stockholders |
|
$ |
(35,007 |
) |
|
$ |
3,852 |
|
|
$ |
(69,680 |
) |
|
$ |
(13,324 |
) |
Net (loss) income per share attributable to Schrödinger common and limited common stockholders, basic: |
|
$ |
(0.49 |
) |
|
$ |
0.06 |
|
|
$ |
(0.99 |
) |
|
$ |
(0.23 |
) |
Weighted average shares used to compute net (loss) income per share attributable to Schrödinger common and limited common stockholders, basic: |
|
|
70,784,184 |
|
|
|
66,339,570 |
|
|
|
70,481,901 |
|
|
|
56,802,567 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net (loss) income per share attributable to Schrödinger common and limited common stockholders, diluted: |
|
$ |
(0.49 |
) |
|
$ |
0.05 |
|
|
$ |
(0.99 |
) |
|
$ |
(0.23 |
) |
Weighted average shares used to compute net (loss) income per share attributable to Schrödinger common and limited common stockholders, diluted: |
|
|
70,784,184 |
|
|
|
72,693,173 |
|
|
|
70,481,901 |
|
|
|
56,802,567 |
|
Condensed Consolidated Balance Sheets (Unaudited) |
|
|||||||
(in thousands, except for share and per share amounts) |
|
|||||||
|
|
|
|
|
|
|
|
|
Assets |
|
September 30, 2021 |
|
|
December 31, 2020 |
|
||
Current assets: |
|
|
|
|
|
|
|
|
Cash and cash equivalents |
|
$ |
160,879 |
|
|
$ |
202,296 |
|
Restricted cash |
|
|
3,000 |
|
|
|
500 |
|
Marketable securities |
|
|
436,307 |
|
|
|
440,395 |
|
Accounts receivable, net of allowance for doubtful accounts of $108 and $60 |
|
|
11,352 |
|
|
|
31,423 |
|
Unbilled and other receivables, net for allowance for unbilled receivables of $20 and $0 |
|
|
4,978 |
|
|
|
3,955 |
|
Prepaid expenses |
|
|
5,509 |
|
|
|
4,409 |
|
Total current assets |
|
|
622,025 |
|
|
|
682,978 |
|
Property and equipment, net |
|
|
9,074 |
|
|
|
5,140 |
|
Equity investments |
|
|
51,087 |
|
|
|
45,664 |
|
Right of use assets |
|
|
76,459 |
|
|
|
10,129 |
|
Other assets |
|
|
3,972 |
|
|
|
2,352 |
|
Total assets |
|
$ |
762,617 |
|
|
$ |
746,263 |
|
Liabilities and Stockholders’ Equity |
|
|
|
|
|
|
|
|
Current liabilities: |
|
|
|
|
|
|
|
|
Accounts payable |
|
$ |
8,228 |
|
|
$ |
8,398 |
|
Accrued payroll, taxes, and benefits |
|
|
14,010 |
|
|
|
12,000 |
|
Deferred revenue |
|
|
43,874 |
|
|
|
45,403 |
|
Lease liabilities |
|
|
1,978 |
|
|
|
4,543 |
|
Other accrued liabilities |
|
|
4,826 |
|
|
|
2,861 |
|
Total current liabilities |
|
|
72,916 |
|
|
|
73,205 |
|
Deferred revenue, long-term |
|
|
32,444 |
|
|
|
41,164 |
|
Lease liabilities, long-term |
|
|
77,135 |
|
|
|
7,221 |
|
Other liabilities, long-term |
|
|
300 |
|
|
|
654 |
|
Total liabilities |
|
|
182,795 |
|
|
|
122,244 |
|
Commitments and contingencies |
|
|
|
|
|
|
|
|
Stockholders' equity: |
|
|
|
|
|
|
|
|
Preferred stock, $0.01 par value. Authorized 10,000,000 shares; zero shares issued and outstanding at September 30, 2021 and December 31, 2020, respectively |
|
|
— |
|
|
|
— |
|
Common stock, $0.01 par value. Authorized 500,000,000 shares; 61,703,441 and 60,713,534 shares issued and outstanding at September 30, 2021 and December 31, 2020, respectively |
|
|
617 |
|
|
|
607 |
|
Limited common stock, $0.01 par value. Authorized 100,000,000 shares; 9,164,193 shares issued and outstanding at September 30, 2021 and December 31, 2020, respectively |
|
|
92 |
|
|
|
92 |
|
Additional paid-in capital |
|
|
778,292 |
|
|
|
752,558 |
|
Accumulated deficit |
|
|
(199,239 |
) |
|
|
(129,559 |
) |
Accumulated other comprehensive income |
|
|
44 |
|
|
|
317 |
|
Total stockholders’ equity of Schrödinger stockholders |
|
|
579,806 |
|
|
|
624,015 |
|
Noncontrolling interest |
|
|
16 |
|
|
|
4 |
|
Total stockholders’ equity |
|
|
579,822 |
|
|
|
624,019 |
|
Total liabilities and stockholders’ equity |
$ |
762,617 |
|
$ |
746,263 |
|||
Condensed Consolidated Statements of Cash Flows (Unaudited) |
|
|||||||
(in thousands) |
|
|||||||
|
|
|
|
|
|
|
|
|
|
|
Nine Months Ended September 30, |
|
|||||
|
|
2021 |
|
|
2020 |
|
||
Cash flows from operating activities: |
|
|
|
|
|
|
|
|
Net loss |
|
$ |
(70,504 |
) |
|
$ |
(15,051 |
) |
Adjustments to reconcile net loss to net cash used in |
|
|
|
|
|
|
|
|
operating activities: |
|
|
|
|
|
|
|
|
Loss (gain) on equity investments |
|
|
1,781 |
|
|
|
(4,156 |
) |
Noncash revenue from equity investments |
|
|
(59 |
) |
|
|
(342 |
) |
Fair value adjustments |
|
|
(19,279 |
) |
|
|
(23,513 |
) |
Depreciation |
|
|
2,195 |
|
|
|
2,648 |
|
Stock-based compensation |
|
|
19,034 |
|
|
|
7,542 |
|
Noncash research and development expenses |
|
|
811 |
|
|
|
1,694 |
|
Noncash investment accretion |
|
|
4,736 |
|
|
|
359 |
|
Loss on disposal of property and equipment |
|
|
140 |
|
|
|
— |
|
Decrease (increase) in assets: |
|
|
|
|
|
|
|
|
Accounts receivable, net |
|
|
20,071 |
|
|
|
6,386 |
|
Unbilled and other receivables |
|
|
(1,358 |
) |
|
|
2,580 |
|
Reduction in the carrying amount of right of use assets |
|
|
4,724 |
|
|
|
3,957 |
|
Prepaid expenses and other assets |
|
|
(2,720 |
) |
|
|
290 |
|
(Decrease) increase in liabilities: |
|
|
|
|
|
|
|
|
Accounts payable |
|
|
(229 |
) |
|
|
1,254 |
|
Accrued payroll, taxes, and benefits |
|
|
2,010 |
|
|
|
668 |
|
Deferred revenue |
|
|
(10,190 |
) |
|
|
(5,258 |
) |
Lease liabilities |
|
|
(3,705 |
) |
|
|
(3,997 |
) |
Other accrued liabilities |
|
|
1,611 |
|
|
|
(1,922 |
) |
Net cash used in operating activities |
|
|
(50,931 |
) |
|
|
(26,861 |
) |
Cash flows from investing activities: |
|
|
|
|
|
|
|
|
Purchases of property and equipment |
|
|
(6,210 |
) |
|
|
(1,652 |
) |
Purchases of equity investments |
|
|
(3,700 |
) |
|
|
(2,869 |
) |
Distribution from equity investment |
|
|
375 |
|
|
|
4,582 |
|
Proceeds from sale of equity investments |
|
|
15,735 |
|
|
|
— |
|
Purchases of marketable securities |
|
|
(340,509 |
) |
|
|
(446,816 |
) |
Proceeds from maturity of marketable securities |
|
|
339,588 |
|
|
|
118,272 |
|
Net cash provided by (used in) investing activities |
|
|
5,279 |
|
|
|
(328,483 |
) |
Cash flows from financing activities: |
|
|
|
|
|
|
|
|
Issuances of common stock upon initial public offering, net |
|
|
— |
|
|
|
211,491 |
|
Issuances of common stock upon follow-on public offering, net |
|
|
— |
|
|
|
325,610 |
|
Issuances of common stock upon stock option exercises |
|
|
6,710 |
|
|
|
2,747 |
|
Contribution by noncontrolling interest |
|
|
25 |
|
|
|
— |
|
Net cash provided by financing activities |
|
|
6,735 |
|
|
|
539,848 |
|
Net (decrease) increase in cash and cash equivalents and restricted cash |
|
|
(38,917 |
) |
|
|
184,504 |
|
Cash and cash equivalents and restricted cash, beginning of period |
|
|
202,796 |
|
|
|
26,486 |
|
Cash and cash equivalents and restricted cash, end of period |
|
$ |
163,879 |
|
|
$ |
210,990 |
|
|
|
|
|
|
|
|
|
|
Supplemental disclosure of cash flow and noncash information |
|
|
|
|
|
|
|
|
Cash paid for income taxes |
|
$ |
236 |
|
|
$ |
225 |
|
Supplemental disclosure of non-cash investing and financing activities |
|
|
|
|
|
|
|
|
Accrued deferred offering costs |
|
|
— |
|
|
|
10 |
|
Purchases of property and equipment in accounts payable |
|
|
59 |
|
|
|
24 |
|
Acquisitions of right of use assets in exchange for lease obligations |
|
|
71,054 |
|
|
|
1,778 |
|
Reclassification of deferred financing costs to additional paid in capital |
|
|
— |
|
|
|
1,858 |
|